CA3039927C - Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2 - Google Patents

Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2 Download PDF

Info

Publication number
CA3039927C
CA3039927C CA3039927A CA3039927A CA3039927C CA 3039927 C CA3039927 C CA 3039927C CA 3039927 A CA3039927 A CA 3039927A CA 3039927 A CA3039927 A CA 3039927A CA 3039927 C CA3039927 C CA 3039927C
Authority
CA
Canada
Prior art keywords
masp
antibody
inhibitory
fibrosis
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3039927A
Other languages
English (en)
Other versions
CA3039927A1 (fr
Inventor
Nigel John Brunskill
Gregory A. Demopulos
Tom DUDLER
Hans-Wilhelm Schwaeble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Priority to CA3210384A priority Critical patent/CA3210384A1/fr
Publication of CA3039927A1 publication Critical patent/CA3039927A1/fr
Application granted granted Critical
Publication of CA3039927C publication Critical patent/CA3039927C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Urology & Nephrology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dans un aspect, l'invention concerne des méthodes de réduction de la protéinurie chez un sujet humain souffrant ou présentant un risque de développer une néphropathie aux immunoglobulines A (IgAN). Les méthodes comprennent l'étape d'administration, à un sujet qui en a besoin, d'une quantité d'un agent inhibiteur de MASP-2 efficace pour inhiber l'activation du complément dépendant de MASP-2.
CA3039927A 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2 Active CA3039927C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3210384A CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US62/407,979 2016-10-13
US15/399,524 2017-01-05
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 2017-03-27
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
US62/527,926 2017-06-30
PCT/US2017/056386 WO2018071701A1 (fr) 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3210384A Division CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Publications (2)

Publication Number Publication Date
CA3039927A1 CA3039927A1 (fr) 2018-04-19
CA3039927C true CA3039927C (fr) 2023-10-10

Family

ID=61906454

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3039927A Active CA3039927C (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2
CA3210384A Pending CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3210384A Pending CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Country Status (18)

Country Link
EP (1) EP3525798A4 (fr)
JP (1) JP6893554B2 (fr)
KR (1) KR102348939B1 (fr)
CN (2) CN110177557A (fr)
AU (1) AU2017342428B2 (fr)
BR (1) BR112019007426A2 (fr)
CA (2) CA3039927C (fr)
CL (2) CL2019000909A1 (fr)
GE (1) GEP20247587B (fr)
IL (1) IL265981A (fr)
JO (1) JOP20190068A1 (fr)
MA (1) MA46541A (fr)
MX (1) MX2019004074A (fr)
PH (1) PH12019500711A1 (fr)
SG (1) SG11201902941UA (fr)
UA (1) UA126908C2 (fr)
WO (1) WO2018071701A1 (fr)
ZA (1) ZA201902933B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2374819T (pt) * 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
MX344322B (es) * 2009-10-16 2016-12-13 Omeros Corp Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vaculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento.
US9102721B2 (en) * 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
NZ746139A (en) * 2011-04-08 2023-11-24 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101641057B1 (ko) * 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
NZ729747A (en) * 2013-03-15 2020-03-27 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
RU2020111211A (ru) * 2013-10-17 2021-11-08 Омерос Корпорейшн Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
IL294411A (en) * 2016-01-05 2022-08-01 Omeros Corp masp-2 suppressors for use in suppressing fibrosis
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
JOP20190068A1 (ar) 2019-04-01
GEP20247587B (en) 2024-01-25
JP2019534271A (ja) 2019-11-28
CN116726163A (zh) 2023-09-12
BR112019007426A2 (pt) 2019-07-02
ZA201902933B (en) 2023-05-31
PH12019500711A1 (en) 2019-11-18
UA126908C2 (uk) 2023-02-22
KR20190063475A (ko) 2019-06-07
CN110177557A (zh) 2019-08-27
MX2019004074A (es) 2019-06-10
MA46541A (fr) 2019-08-21
SG11201902941UA (en) 2019-05-30
CA3210384A1 (fr) 2018-04-19
JP6893554B2 (ja) 2021-06-23
WO2018071701A1 (fr) 2018-04-19
EP3525798A4 (fr) 2020-07-08
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
EP3525798A1 (fr) 2019-08-21
NZ753260A (en) 2021-11-26
IL265981A (en) 2019-06-30
AU2017342428A1 (en) 2019-05-23
KR102348939B1 (ko) 2022-01-12
AU2017342428B2 (en) 2021-02-04
CA3039927A1 (fr) 2018-04-19

Similar Documents

Publication Publication Date Title
US12005117B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
US20210079116A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
US20210355236A1 (en) Methods for inhibiting fibrosis in a subject in need thereof
TWI834025B (zh) 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
CA3039927C (fr) Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2
OA18820A (en) Methods for inhibiting fibrosis in a subject in need thereof.
OA19229A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy.
EA043102B1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409

EEER Examination request

Effective date: 20190409